23:44 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:PTE) hired Matt Kemp as chief commercial officer, a newly created position. He was CCO at Dendreon Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China)....
18:23 , May 25, 2018 |  BC Week In Review  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
15:04 , May 18, 2018 |  BC Extra  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and...
23:58 , Apr 19, 2018 |  BC Innovations  |  Product R&D

Automation navigation

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
22:14 , Nov 10, 2017 |  BC Extra  |  Company News

Management tracks: Immunomedics, WuXi

Antibody company Immunomedics Inc. (NASDAQ:IMMU) appointed Michael Pehl president and CEO, effective Dec. 7, and Brendan Delaney chief commercial officer. Interim CEO Michael Garone will resume his role as CFO. Pehl was president of hematology...
00:59 , Sep 2, 2017 |  BioCentury  |  Strategy

Pathfinding for access

A pact with the Centers for Medicare & Medicaid Services for Novartis AG ’s CAR T therapy demonstrates leadership in new value-based drug pricing models. Kymriah tisagenlecleucel represents a milestone for three reasons. Its approval...
18:45 , Jul 6, 2017 |  BC Week In Review  |  Company News

Sanpower completes acquisition of Dendreon from Valeant

Sanpower Group Co. Ltd. (Nanjing, China) completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global...
23:15 , Jun 30, 2017 |  BC Extra  |  Company News

Sanpower completes Dendreon acquisition

Sanpower Group Co. Ltd. (Nanjing, China) said it completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets,...
20:35 , Apr 21, 2017 |  BC Week In Review  |  Company News

Alpine, Nivalis deal

Immunology company Alpine will reverse-merge cystic fibrosis play Nivalis in a stock deal. The combined entity will retain Alpine’s name and will trade on NASDAQ under a new ticker. Alpine’s current CEO, Mitchell Gold, will...
23:24 , Apr 18, 2017 |  BC Extra  |  Company News

Alpine finds public path through Nivalis

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will...